The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients
- PMID: 22797868
- PMCID: PMC3664759
- DOI: 10.1007/s11136-012-0230-7
The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients
Abstract
Objective: The Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) has been shown to have good psychometric performance in measuring headache impact in migraine patients, but its properties specifically in chronic migraine (CM) patients are unknown. The objective of this study was to evaluate the psychometric properties of the MSQ in a group of CM patients undergoing prophylactic treatment.
Methods: Measurement properties of the MSQ were examined using two international, multicenter, randomized clinical trials evaluating onabotulinumtoxinA as headache prophylaxis in CM patients (N = 1,376). Confirmatory factor analysis (CFA) was used to test the latent structure of the MSQ in CM patients. The reliability, convergent and discriminant validity, and responsiveness of the MSQ were assessed.
Results: CFA confirmed the currently proposed three-factor MSQ latent structure across the two studies. Good reliability was observed for all three MSQ scales, across studies and time points. MSQ scale scores strongly correlated with the scores of the Headache Impact Test-6 (HIT-6). Analysis of known-groups validity indicated that MSQ scale scores discriminated between groups of patients differing in their 28-day headache frequency were as follows <10, 10-14, and ≥ 15 days, and the sample-derived quartiles of the total cumulative hours of headache were as follows <140, 140 to <280, 280 to <420, and ≥ 420 h (p < 0.0001), across both studies and time points. MSQ change scores were higher in magnitude in groups experiencing greater decline in headache frequency (p < 0.001).
Conclusion: The MSQ is a psychometrically valid tool that can be used to reliably measure the impact of migraine among CM patients.
Similar articles
-
Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.Headache. 2012 Mar;52(3):409-21. doi: 10.1111/j.1526-4610.2011.01997.x. Epub 2011 Sep 19. Headache. 2012. PMID: 21929662
-
Validity, reliability, and sensitivity to change of the Arabic version of the Migraine-Specific Quality-of-Life Questionnaire after prophylactic treatment.Headache. 2025 May;65(5):770-778. doi: 10.1111/head.14874. Epub 2024 Nov 27. Headache. 2025. PMID: 39601107
-
Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine.Health Qual Life Outcomes. 2014 Aug 1;12:117. doi: 10.1186/s12955-014-0117-0. Health Qual Life Outcomes. 2014. PMID: 25080874 Free PMC article.
-
Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment.Qual Life Res. 2007 Sep;16(7):1231-7. doi: 10.1007/s11136-007-9217-1. Epub 2007 Apr 28. Qual Life Res. 2007. PMID: 17468941
-
Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs).Cephalalgia. 2018 Jun;38(7):1374-1386. doi: 10.1177/0333102417731348. Epub 2017 Sep 18. Cephalalgia. 2018. PMID: 28920448 Free PMC article.
Cited by
-
Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.J Headache Pain. 2021 May 28;22(1):48. doi: 10.1186/s10194-021-01222-w. J Headache Pain. 2021. PMID: 34049484 Free PMC article. Clinical Trial.
-
Factors and Reasons Associated with Hesitating to Seek Care for Migraine: Results of the OVERCOME (US) Study.Neurol Ther. 2025 Feb;14(1):135-155. doi: 10.1007/s40120-024-00668-9. Epub 2024 Nov 2. Neurol Ther. 2025. PMID: 39487945 Free PMC article.
-
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.Headache. 2020 Nov;60(10):2304-2319. doi: 10.1111/head.14013. Headache. 2020. PMID: 33249580 Free PMC article. Clinical Trial.
-
Effect of fremanezumab on quality of life and productivity in patients with chronic migraine.Neurology. 2020 Aug 18;95(7):e878-e888. doi: 10.1212/WNL.0000000000010000. Epub 2020 Aug 3. Neurology. 2020. PMID: 32747522 Free PMC article.
-
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.J Headache Pain. 2019 Jan 22;20(1):10. doi: 10.1186/s10194-018-0952-1. J Headache Pain. 2019. PMID: 30669961 Free PMC article.
References
-
- Dahlof CG. Measuring disability and quality of life in migraine. Drugs Today (Barcelona) 2003;39(Suppl D):17–23. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical